Predictors of prostate carcinoma in PSA gray zone patients with PI-RADS score of 3

Coşkun Bostancı; Kazım Erdem; Ufuk Bozkurt; Meriç Doğukan Demir; Muhammed Cemre Cevrin; Ferhat Yıldız

Article Details

Predictors of prostate carcinoma in PSA gray zone patients with PI-RADS score of 3

Authors:

Coşkun Bostancı | Kazım Erdem | Ufuk Bozkurt | Meriç Doğukan Demir | Muhammed Cemre Cevrin | Ferhat Yıldız

Publisher:

Ondokuz Mayıs University

Main Topics:

Urology

Journal:

Deneysel ve Klinik Tıp Dergisi Vol.41 Issue 2, pp.317-323

Document Type:

Article

Publication Date:

5/2024

Document Language:

English

Document ID (Org No.):

2001317663

pISSN:

1309-4483

Keywords:

Abstract:

 Our aim was to evaluate the predictors of prostate cancer and clinically significant prostate cancer in patients with prostate-specific antigen PSA level between 4-10 ngml who had pre-biopsy Prostate ImagingReporting and Data System PI-RADS score of 3. The study analyzed data from 94 patients who underwent transrectal prostate biopsy with the PI-RADS score of 3 between January 2019 and December 2023. The detection rates of prostate cancer and clinically significant prostate cancer were calculated. Simple and multiple logistic regression analysis were conducted to evaluate the predictors of prostate cancer and clinically significant prostate cancer. The receiver operating characteristics curve analysis and area under curve values were used to determine the priority of parameters. In our study, the incidence of PI-RADS 3 lesion was 18.5. The overall prostate cancer detection rate was 38.2 with the clinically significant prostate cancer detection rate was 22.3. For prostate carcinoma and clinically significant prostate carcinoma logistic regression analysis revealed that free to total prostate-specific antigen ft PSA ratio and age were the independent predictors. Receiver Operating Characteristic curve analysis and area under curve revealed that ft PSA ratio had the highest value 0.770 followed by prostate volume PV 0,751 for clinically significant prostate cancer. Prostate-specific antigen density PSAD had the third highest area under curve value of 0.739. Although current guidelines recommend not performing biopsy for patients with PSAD0.10 ngmlcc in patients with PI-RADS score 3, our clinically significant prostate cancer detection rate was 13 with this level. Therefore, we recommend that each patient should be evaluated individually with PI-RADS score 3. For deciding on biopsy, not only PSAD but also ft PSA and PV should be considered, especially in PSA gray zone patients. However, further studies with more patients are required to validate this recommendation.

 Our aim was to evaluate the predictors of prostate cancer and clinically significant prostate cancer in patients with prostate-specific antigen PSA level between 4-10 ngml who had pre-biopsy Prostate ImagingReporting and Data System PI-RADS score of 3. The study analyzed data from 94 patients who underwent transrectal prostate biopsy with the PI-RADS score of 3 between January 2019 and December 2023. The detection rates of prostate cancer and clinically significant prostate cancer were calculated. Simple and multiple logistic regression analysis were conducted to evaluate the predictors of prostate cancer and clinically significant prostate cancer. The receiver operating characteristics curve analysis and area under curve values were used to determine the priority of parameters. In our study, the incidence of PI-RADS 3 lesion was 18.5. The overall prostate cancer detection rate was 38.2 with the clinically significant prostate cancer detection rate was 22.3. For prostate carcinoma and clinically significant prostate carcinoma logistic regression analysis revealed that free to total prostate-specific antigen ft PSA ratio and age were the independent predictors. Receiver Operating Characteristic curve analysis and area under curve revealed that ft PSA ratio had the highest value 0.770 followed by prostate volume PV 0,751 for clinically significant prostate cancer. Prostate-specific antigen density PSAD had the third highest area under curve value of 0.739. Although current guidelines recommend not performing biopsy for patients with PSAD0.10 ngmlcc in patients with PI-RADS score 3, our clinically significant prostate cancer detection rate was 13 with this level. Therefore, we recommend that each patient should be evaluated individually with PI-RADS score 3. For deciding on biopsy, not only PSAD but also ft PSA and PV should be considered, especially in PSA gray zone patients. However, further studies with more patients are required to validate this recommendation.

 Our aim was to evaluate the predictors of prostate cancer and clinically significant prostate cancer in patients with prostate-specific antigen PSA level between 4-10 ngml who had pre-biopsy Prostate ImagingReporting and Data System PI-RADS score of 3. The study analyzed data from 94 patients who underwent transrectal prostate biopsy with the PI-RADS score of 3 between January 2019 and December 2023. The detection rates of prostate cancer and clinically significant prostate cancer were calculated. Simple and multiple logistic regression analysis were conducted to evaluate the predictors of prostate cancer and clinically significant prostate cancer. The receiver operating characteristics curve analysis and area under curve values were used to determine the priority of parameters. In our study, the incidence of PI-RADS 3 lesion was 18.5. The overall prostate cancer detection rate was 38.2 with the clinically significant prostate cancer detection rate was 22.3. For prostate carcinoma and clinically significant prostate carcinoma logistic regression analysis revealed that free to total prostate-specific antigen ft PSA ratio and age were the independent predictors. Receiver Operating Characteristic curve analysis and area under curve revealed that ft PSA ratio had the highest value 0.770 followed by prostate volume PV 0,751 for clinically significant prostate cancer. Prostate-specific antigen density PSAD had the third highest area under curve value of 0.739. Although current guidelines recommend not performing biopsy for patients with PSAD0.10 ngmlcc in patients with PI-RADS score 3, our clinically significant prostate cancer detection rate was 13 with this level. Therefore, we recommend that each patient should be evaluated individually with PI-RADS score 3. For deciding on biopsy, not only PSAD but also ft PSA and PV should be considered, especially in PSA gray zone patients. However, further studies with more patients are required to validate this recommendation.

 Our aim was to evaluate the predictors of prostate cancer and clinically significant prostate cancer in patients with prostate-specific antigen PSA level between 4-10 ngml who had pre-biopsy Prostate ImagingReporting and Data System PI-RADS score of 3. The study analyzed data from 94 patients who underwent transrectal prostate biopsy with the PI-RADS score of 3 between January 2019 and December 2023. The detection rates of prostate cancer and clinically significant prostate cancer were calculated. Simple and multiple logistic regression analysis were conducted to evaluate the predictors of prostate cancer and clinically significant prostate cancer. The receiver operating characteristics curve analysis and area under curve values were used to determine the priority of parameters. In our study, the incidence of PI-RADS 3 lesion was 18.5. The overall prostate cancer detection rate was 38.2 with the clinically significant prostate cancer detection rate was 22.3. For prostate carcinoma and clinically significant prostate carcinoma logistic regression analysis revealed that free to total prostate-specific antigen ft PSA ratio and age were the independent predictors. Receiver Operating Characteristic curve analysis and area under curve revealed that ft PSA ratio had the highest value 0.770 followed by prostate volume PV 0,751 for clinically significant prostate cancer. Prostate-specific antigen density PSAD had the third highest area under curve value of 0.739. Although current guidelines recommend not performing biopsy for patients with PSAD0.10 ngmlcc in patients with PI-RADS score 3, our clinically significant prostate cancer detection rate was 13 with this level. Therefore, we recommend that each patient should be evaluated individually with PI-RADS score 3. For deciding on biopsy, not only PSAD but also ft PSA and PV should be considered, especially in PSA gray zone patients. However, further studies with more patients are required to validate this recommendation.

Article Details

Predictors of prostate carcinoma in PSA gray zone patients with PI-RADS score of 3

Authors:

Coşkun Bostancı | Kazım Erdem | Ufuk Bozkurt | Meriç Doğukan Demir | Muhammed Cemre Cevrin | Ferhat Yıldız

Publisher:

Ondokuz Mayıs University

Main Topics:

Urology

Journal:

Deneysel ve Klinik Tıp Dergisi Vol.41 Issue 2, pp.317-323

Document Type:

Article

Publication Date:

5/2024

Document Language:

English

Document ID (Org No.):

2001317663

pISSN:

1309-4483

prostate biopsy

PI-RADS

prostate-specific antigen density

prostate cancer

Issues

Article Details

Predictors of prostate carcinoma in PSA gray zone patients with PI-RADS score of 3

Authors: Coşkun Bostancı | Kazım Erdem | Ufuk Bozkurt | Meriç Doğukan Demir | Muhammed Cemre Cevrin | Ferhat Yıldız

Publisher: Ondokuz Mayıs University

Main Topics: Urology

Journal: Deneysel ve Klinik Tıp Dergisi Vol.41 Issue 2, pp.317-323

Document Type: Article

Publication Date: 5/2024

Document Language: English

Document ID (Org No.): 2001317663

pISSN: 1309-4483

prostate biopsy

PI-RADS

prostate-specific antigen density

prostate cancer

Issues

Authors:

Coşkun Bostancı | Kazım Erdem | Ufuk Bozkurt | Meriç Doğukan Demir | Muhammed Cemre Cevrin | Ferhat Yıldız

Publisher:

Ondokuz Mayıs University

Main Topics:

Urology

Journal:

Deneysel ve Klinik Tıp Dergisi Vol.41 Issue 2, pp.317-323

Document Type:

Article

Publication Date:

5/2024

Document Language:

English

Document ID (Org No.):

2001317663

pISSN:

1309-4483